Catalog No.
Product Name
Application
Product Information
Citations
-
HBV Capsid Assembly Modulator
CAB7-3 is an orally active capsid assembly modulator targeting Hepatitis B Virus (HBV), exhibiting potent antiviral activity. It demonstrates significant efficacy with EC50 values of 70 nM in HepDES19 cells, 1 nM in HepAD38 cells, and 2 nM in HBV-infected HLCZ01 cells. CAB7-3 effectively reduces hepatic HBV core protein levels and suppresses viral replication in vivo. This compound is valuable for research aimed at understanding and treating HBV infections. -
Reverse Transcriptase Inhibitor
Lamivudine triphosphate is a potent reverse transcriptase inhibitor that serves as a phosphorylated form of the nucleoside analogue Lamivudine. It effectively disrupts the replication of HIV and HBV viruses through chain termination. Additionally, Lamivudine triphosphate inhibits the RNA-dependent RNA polymerase (RdRp) activity of the NS5B subunit in hepatitis C virus, and can be incorporated into nascent RNA by the SARS-CoV-2 RdRp, thereby preventing mutations in the SARS-CoV-2 RNA. This makes it a valuable reagent for research on viral replication mechanisms and antiviral drug development. -
HBV Inhibitor
GS-8873 is an orally active inhibitor targeting hepatitis B virus (HBV) surface antigen (HBsAg) production, exhibiting an EC50 of 4 nM. This compound demonstrates favorable pharmacokinetic properties in rat models and shows metabolic stability in human hepatocytes. While GS-8873 effectively suppresses HBV, it has been associated with neurofunctional deficits in both rats and cynomolgus monkeys, making it a subject of interest for further research into its biological effects and therapeutic potential. -
HBV Inhibitor
(Rac)-AB-423 is a novel inhibitor targeting hepatitis B virus (HBV) with demonstrated antiviral activity. This compound has shown no induction of CYP1A2, CYP3A4, or CYP2B6 enzymes at elevated concentrations, indicating a favorable safety profile. Additionally, (Rac)-AB-423 exhibits advantageous pharmacokinetic characteristics, including high oral bioavailability and systemic exposure. In preclinical studies using a hydrodynamic injection HBV mouse model, (Rac)-AB-423 achieved a viral load reduction exceeding 2 log, highlighting its potential for therapeutic applications in HBV management. -
Anti-HBV Agent
Schisanwilsonin C is an anti-HBV agent that demonstrates significant activity against hepatitis B virus. This compound has been studied for its potential in antiviral research, offering insights into therapeutic strategies for managing HBV infections. Its efficacy in targeting viral replication makes it a valuable tool for further investigations in hepatitis B research. -
HBV Control
(1R,3S,4R)-ent-Entecavir is an inhibitor of hepatitis B virus (HBV) replication, primarily targeting viral DNA polymerase. This compound is valuable for research applications focused on HBV control and offers potential for the development of PROTACs aimed at degrading viral DNA polymerase. Its structural analog attributes enhance its utility in studying antiviral mechanisms and therapeutic strategies against HBV infection. -
HBV Inhibitor
HBV-IN-20 is a potent oral active inhibitor of Hepatitis B Virus (HBV), functioning primarily as a type II core protein assembly modulator (CpAM). With an EC50 of 0.46 µM, HBV-IN-20 disrupts the assembly of HBV core particles, thereby impeding viral replication. This compound is particularly valuable for research applications focused on antiviral therapy and understanding HBV biology. -
HBV Inhibitor
AB-161 is an orally active HBV RNA destabilizer and a selective inhibitor of poly(A) polymerase domain-containing proteins 5 and 7 (PAPD5/7), primarily targeting hepatic tissues. This compound is effective in treating Hepatitis B Virus (HBV) infections by significantly reducing the levels of Hepatitis B surface antigen (HBsAg), with an EC50 value of 2.2 nM for HBsAg. AB-161 is a valuable tool for research applications focused on understanding and addressing HBV infection. -
HBV Inhibitor
LP10 is a non-azole inhibitor targeting CYP51, showing potent activity against Hepatitis B Virus (HBV). This compound disrupts viral replication by inhibiting 14α-demethylation, which is critical for cholesterol biosynthesis in the virus. LP10 is useful for studying HBV infection mechanisms and evaluating antiviral strategies. -
Nucleoside Reverse Transcriptase Inhibitor
Metacavir is a potent nucleoside reverse transcriptase inhibitor primarily targeting the hepatitis B virus (HBV). This orally active compound exhibits significant antiviral activity, making it a valuable tool in the research of antiviral therapies and the development of treatments for HBV infections. Its specificity and efficacy in inhibiting reverse transcriptase contribute to its potential application in studying hepatitis B and related disorders. -
HBV Inhibitor
DVR-01 is a hepatitis B virus (HBV) inhibitor that exhibits antiviral activity in AML12HBV10 and HepDES19 cell lines, with EC50 values of 1.7 and 1.6 μM, respectively. This compound also demonstrates efficacy against drug-resistant HBV mutants, exhibiting EC50 values ranging from 2.403 to 3.273 μM. DVR-01 is suitable for research applications focused on HBV infection and associated diseases, contributing to the understanding of viral mechanisms and potential therapeutic interventions. -
Anti-HBV Agent
Lagociclovir valactate is a prodrug of Lagociclovir, designed for oral administration as an anti-hepatitis B virus (HBV) agent. It exhibits potent antiviral activity against HBV, making it valuable for research related to viral infections and hepatitis B treatment strategies. This compound aids in the exploration of effective therapeutic options in the management of HBV-related diseases. -
HBV Inhibitor
KKJ00626 is a potent inhibitor of Hepatitis B virus (HBV) with an IC50 of 0.12 to 0.23 μM. This compound targets the interaction between HBV core protein and the surface protein PreS region, effectively preventing the maturation and secretion of HBV particles. Its significant antiviral activity makes KKJ00626 a valuable tool for research in HBV therapeutics and virology studies. -
Anti-HBV Agent
Dihydrodehydrodiconiferyl alcohol 9-O-β-D-xylopyranoside is a compound targeting hepatitis B virus (HBV) through the inhibition of HBV surface antigen (HBsAg) and HBV e antigen (HBeAg) secretion. This agent has demonstrated effective antiviral activity in the Hep G2.2.15 cell line, with IC50 values of 1.67 mM for HBsAg and greater than 2.15 mM for HBeAg. It is beneficial for research focusing on HBV infection and therapeutic development against hepatitis B. -
HBV/HDV Inhibitor
HBV/HDV-IN-5 is a potent inhibitor targeting hepatitis B virus (HBV) and hepatitis D virus (HDV). This compound exhibits significant antiviral activity, making it valuable for research focused on viral hepatitis. HBV/HDV-IN-5 is primarily utilized in studies exploring antiviral therapies and the mechanisms underlying HBV and HDV infections. -
anti-HBV/HIV-1 Agent
Periglaucine A is a hasubanane-type alkaloid that targets anti-HBV and anti-HIV-1 activity. It effectively inhibits the secretion of HBV surface antigen (HBsAg) in Hep G2.2.15 cells, demonstrating its potential as a therapeutic agent against hepatitis B virus. Additionally, Periglaucine A exhibits anti-HIV-1 efficacy in C8166 cells, with an EC50 value of 204 μM, making it a valuable compound for research in viral infections. -
Anti-HBV Natural Compound
Acutumidine is an alkaloid known for its anti-HBV activity, derived from the plant Hypserpa nitida Miers. This compound effectively inhibits the production of hepatitis B surface antigen (HBsAg) in Hep G2.2.15 cells that are stably transfected with the HBV genome, demonstrating an IC50 value of 2.023 mM. Acutumidine shows potential for research applications in the study of hepatitis B virus infection and its pathways. -
HBV Inhibitor
Morphothiadin mesylate is a potent inhibitor of Hepatitis B Virus (HBV) replication, targeting both wild-type and Adefovir-resistant strains. With an IC50 value of 12 nM, it demonstrates significant antiviral activity. This compound is useful for research applications focused on HBV pathogenesis and the development of antiviral therapeutic strategies. -
Anti-HBV Agent
HBV-IN-49 is an anti-hepatitis B virus (HBV) agent that specifically inhibits HBV replication. It is valuable for studying HBV infection dynamics and evaluating therapeutic strategies against hepatitis B virus-related diseases. This compound serves as an essential tool for researchers investigating antiviral mechanisms and potential treatments. -
HBV Inhibitor
Coclauril is a potent inhibitor of Hepatitis B virus (HBV) replication, acting primarily on hepatocytes. It demonstrates antiviral activity in human hepatoblastoma cell lines, with an EC50 value of 7.6 μg/mL. Coclauril is utilized in research to explore therapeutic strategies against HBV and to study the mechanisms of viral replication inhibition. -
HBV Inhibitor
BAY39-5493 is a non-nucleoside inhibitor targeting hepatitis B virus (HBV) replication. It exerts its biological activity by blocking the formation of viral core particles, thereby inhibiting viral DNA replication. With an IC50 value of 0.03 μM against HBV in stably transfected HepG2.2.15 cells, BAY39-5493 serves as a valuable tool for research in the field of antiviral therapeutics and HBV biology. -
HBV Inhibitor
BAY38-7690 is a non-nucleoside inhibitor that specifically targets hepatitis B virus (HBV) replication. It functions by obstructing the assembly of viral core particles, thereby inhibiting viral DNA replication. With an IC50 value of 0.15 μM in stably transfected HepG2.2.15 cells, BAY38-7690 is an important tool for investigating HBV biology and evaluating potential therapeutic strategies against hepatitis B virus infections. -
HBV Capsid Assembly Regulator
KR-26556 is a sulfonamide compound that acts as a hepatitis B virus (HBV) capsid assembly regulator. It demonstrates potent anti-HBV activity with an EC50 value of 0.04 μM and exhibits favorable safety profiles. This reagent is suitable for investigating chronic hepatitis B and its associated therapeutic mechanisms. -
HBV Inhibitor
Personalised postprandial-targeting is an HBV inhibitor that modulates water-heme interactions, specifically targeting low-spin cytochrome P450 complexes. This reagent effectively preserves the axial water ligands of CYP2C9, even when inhibitors are present, enabling advanced studies of enzyme dynamics. Additionally, it facilitates the observation of hydrogen atoms in the axial water ligands through EPR spectroscopy, offering valuable insights into the active site of the enzyme, making it a critical tool for research in enzymology and drug development. -
HBV Inhibitor
GS-8873 TFA is a potent inhibitor of hepatitis B virus (HBV) surface antigen (HBsAg) production, exhibiting an EC50 value of 4 nM. This orally bioavailable compound demonstrates favorable pharmacokinetic properties in rodent models and metabolic stability in human hepatocytes. Notably, GS-8873 TFA has been associated with neurofunctional deficits in both rats and cynomolgus monkeys, making it a valuable tool for research in HBV therapies and associated neurological effects. -
Nucleotide Reverse Transcriptase Inhibitor
Tenofovir disoproxil aspartate is a nucleotide reverse transcriptase inhibitor primarily targeting HIV and chronic Hepatitis B. It demonstrates potent antiviral activity by interfering with viral RNA replication, ultimately leading to reduced viral load in infected patients. This compound is essential in research aimed at developing effective therapeutic strategies against retroviral infections. -
HCV/SARS-CoV-2 Inhibitor
Bemnifosbuvir is a potent inhibitor of Hepatitis C virus (HCV) replication with demonstrated efficacy against SARS-CoV-2. This orally active compound exhibits significant antiviral activity in vitro, achieving an effective concentration (EC90) of 0.47 μM against COVID-19. Bemnifosbuvir displays pangenotypic activity, making it a valuable tool for research into antiviral therapies for both HCV and SARS-CoV-2 infections. -
HCV/SARS-CoV-2 Inhibitor
Bemnifosbuvir hemisulfate is a potent inhibitor of HCV viral replication and a promising antiviral agent against SARS-CoV-2. This guanosine nucleotide proagent exhibits significant efficacy in vitro, demonstrating an EC90 value of 0.47 μM against COVID-19. Bemnifosbuvir hemisulfate also shows pangenotypic antiviral activity, making it a valuable tool for research in viral infections and therapeutic development. -
IRF3 Activator
KIN1400 is a potent IRF3 activator that stimulates the expression of IRF3-dependent antiviral genes, including RIG-I, MDA5, IFIT1, and Mx1, as well as IFN-β production. This compound effectively inhibits the replication of West Nile Virus (WNV) and Dengue Virus (DV), both of which are mosquito-borne flaviviruses, as well as Hepatitis C Virus (HCV). KIN1400 activates innate antiviral immunity via the MAVS-IRF3 signaling pathway, making it a valuable tool for research focused on antiviral responses and immune modulation. -
HCV/HIV Inhibitor
C5A is a microbicidal peptide that targets and inhibits both hepatitis C virus (HCV) and human immunodeficiency virus (HIV). By disrupting the membrane integrity of the HIV virion and affecting the conical capsid core that encases the viral genome, C5A significantly reduces the infectivity of a wide range of HIV isolates in various primary target cells in vitro. Additionally, studies have demonstrated that C5A offers protective effects in mice against vaginal and rectal challenges with HIV, highlighting its potential utility in antiviral research applications. -
COVID-19 Inhibitor
RBT-9 is a COVID-19 inhibitor that targets viral replication and inflammation pathways. It has demonstrated efficacy in preventing the progression to severe COVID-19 and associated organ failure. Furthermore, RBT-9 exhibits antiviral activity against various enveloped viruses, including influenza, hepatitis C virus (HCV), dengue, and yellow fever, making it a valuable tool for research in viral pathogenesis and therapeutic intervention. -
Serine β-Lactamase Inhibitor
Pilabactam is a potent covalent inhibitor of serine β-lactamases, exhibiting IC50 values between 1 nM and 175 nM across various serine β-lactamase types. This compound significantly enhances the efficacy of β-lactam antibiotics against challenging pathogens such as Carbapenem-Resistant Enterobacterales (CRE) and Acinetobacter baumannii (CRAB). Pilabactam is valuable in research focused on bacterial infections and antibiotic resistance mechanisms. -
Antibacterial Agent
HSGN-218 is an antibacterial agent that demonstrates potent efficacy against various strains of Clostridium difficile, exhibiting minimum inhibitory concentration (MIC) values between 0.007 μM and 0.07 μM. Despite its low permeability across Caco-2 cells, HSGN-218 is a valuable tool for investigating bacterial growth inhibition and exploring therapeutic options for C. difficile infections in research applications. -
Bacterial Inhibitor
Pyrroxamycin is a novel antibiotic with a primary mechanism targeting Gram-positive bacteria and dermatophytes. Derived from the fermentation of Streptomyces, it exhibits potent antibacterial activity. This compound has potential applications in pharmaceutical research for the development of new antimicrobials, particularly against resistant bacterial strains. Detailed analysis of its chemical structure was performed using X-ray crystallography and 13C NMR spectroscopy, elucidating its physicochemical properties and enhancing its utility in microbiological studies. -
Antibacterial Agent
Antibacterial Agent 39 is a potent antibacterial compound that demonstrates synergistic effects by significantly lowering the minimum inhibitory concentration (MIC) of Ceftazidime. This compound exhibits strong antibacterial activity against various Gram-negative bacteria, making it a valuable tool for research focused on combating antibiotic resistance and enhancing the efficacy of existing antibiotics. Its application in microbiological studies can provide insights into the mechanisms of action and interactions between different antibacterial agents. -
Quorum Sensing Inhibitor
Aculene D is a quorum sensing inhibitor derived from fungal metabolites that targets the signaling mechanisms in bacteria. It effectively reduces violacein production in Chromobacterium violaceum CV026 cultures induced by N-hexanoyl-L-homoserine lactone (C6-HSL) at sub-inhibitory concentrations. This compound is valuable for research exploring bacterial communication and the modulation of biofilm formation, with potential applications in combating antibiotic resistance and developing new antimicrobial strategies. -
Anti-Bacterial Agent
Juncuenin D is an anti-bacterial agent known for its ability to induce caspase-3-mediated cytotoxicity in HT22 cells. This compound exhibits significant anti-bacterial activity against methicillin-resistant Staphylococcus aureus (MRSA) strains. Juncuenin D is derived from Juncus effusus and serves as a valuable tool for research in infectious disease and cell death mechanisms. -
Antibacterial Peptide
Latarcin 2a is a linear cationic antibacterial peptide derived from the venom of the spider Lachesana tarabaevi, exhibiting broad-spectrum antibacterial activity. It demonstrates a minimum inhibitory concentration (MIC) of 0.5 μM against both Bacillus subtilis and Escherichia coli. This peptide is primarily utilized in research related to infectious diseases and the development of novel antimicrobial agents. -
β-lactamase Inhibitor
β-Lactamase-IN-5 is a potent β-lactamase inhibitor that serves to enhance the efficacy of β-lactam antibiotics against resistant bacterial strains. Its primary mechanism involves the inhibition of β-lactamase enzymes, which are responsible for antibiotic resistance. This compound is valuable for research applications aimed at understanding and combating bacterial infections, particularly those caused by multidrug-resistant pathogens. -
Antibacterial Agent
Antibacterial Agent 60 is a potent antibacterial compound that enhances the efficacy of Ceftazidime by significantly reducing its minimum inhibitory concentration (MIC). This agent exhibits strong antibacterial activity, making it particularly useful in overcoming bacterial resistance. It can be employed in various research applications focused on developing improved antimicrobial therapies and optimizing existing antibiotics against resistant strains. -
Bacterial Inhibitor
β-Lactamase-IN-6 is a potent inhibitor of β-Lactamase enzymes, which play a crucial role in bacterial resistance to β-lactam antibiotics. This compound demonstrates significant antibacterial activity by preventing the enzymatic breakdown of β-lactam antibiotics, thereby enhancing their effectiveness against resistant bacterial strains. β-Lactamase-IN-6 serves as a valuable tool in microbiological research and antibiotic development, providing insights into combating bacterial infections and resistance mechanisms. -
Antibacterial Agent
Antibacterial Agent 51 primarily targets bacterial cell growth and division. It exhibits minimum inhibitory concentration (MIC) values of 4 mcg/mL against E. coli NCTC 13351 and 8 mcg/mL against both E. coli strains M 50 and 7 MP. This compound is valuable for research applications focused on bacterial resistance and the development of new antibacterial therapies. -
Bacterial Inhibitor
(R)-Gyramide A hydrochloride is a bacterial DNA gyrase inhibitor that effectively disrupts DNA supercoiling, exhibiting an IC50 of 3.3 µM. This compound demonstrates significant antibacterial activity against Escherichia coli, Pseudomonas aeruginosa, and Salmonella enterica, with minimum inhibitory concentrations ranging from 10 to 80 µM. Notably, (R)-Gyramide A hydrochloride does not inhibit topoisomerase IV, making it a valuable tool for studying bacterial mechanisms and antibiotic resistance. -
Antibacterial Agent
Heronapyrrole B is a Gram-positive-selective antibacterial agent with an IC50 range of 0.6-1.1 μM against Staphylococcus aureus ATCC9144. This compound demonstrates potent antibacterial activity, making it a valuable tool in the study of bacterial infections. Its specific mechanism of action and efficacy position it for potential applications in antibiotic research and development. -
Antibacterial Agent
Antibacterial Agent 192 is an antibacterial compound that targets and disrupts iron homeostasis in Escherichia coli. This mechanism leads to impaired bacterial growth and viability, making it a valuable tool for studying bacterial metabolism and resistance mechanisms. Its applications include research in antibiotic development and the investigation of bacterial iron regulation processes. -
Antimycobacterial Agent
3β,7β,15β-Trihydroxy-11-oxo-lanosta-8-en-24→20 lactone is a natural compound with noted antimycobacterial activity. Isolated from Ganoderma lucidum, this compound demonstrates effectiveness against mycobacterial infections, making it a valuable resource in antibacterial research. Its unique structure and biological properties render it a promising candidate for further investigation in the development of antimycobacterial therapies. -
Antibacterial Agent
Ro 24-4383 is a carbamate-linked compound that exhibits antibacterial activity through a dual mechanism of action. It effectively targets bacterial cell processes, making it a valuable tool in antibacterial research. This compound is useful for studies related to bacterial resistance and the development of new antibacterial therapies. -
Bacterial
B1912 is an antibacterial compound that demonstrates significant efficacy against various bacterial strains. Its primary mechanism involves disrupting bacterial cell wall synthesis, leading to cell lysis and death. This reagent is valuable for research applications focused on developing new antibacterial therapies and studying bacterial resistance mechanisms. -
Antibacterial Agent
DPI-2016 is an antibacterial agent that demonstrates potent bactericidal activity, with minimum inhibitory concentrations (MIC) ranging from 0.25 to 8 μg/mL across various bacterial strains. This compound exhibits enhanced effectiveness compared to standard treatments such as aztreonam, which has MIC values between 16 and greater than 64 μg/mL. DPI-2016 is suitable for research applications aimed at investigating bacterial resistance and efficacy in therapeutic interventions. -
Antibacterial Agent
Bauer-7-ene-3β,16α-diol is a triterpenoid with demonstrated antibacterial properties, primarily targeting bacterial strains such as E. coli. Isolated from the dried flower buds of Tussilago farfara L. or Petasites tricholobus, it exhibits medium antibacterial activity, making it a valuable reagent for research in natural product pharmacology and the development of antimicrobial agents. Its structural features and potency may facilitate investigations into the mechanisms of bacterial resistance and alternative therapeutic strategies.
